Tyr185
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr185  -  JNK1 (mouse)

Site Information
tsFMMtPyVVtRYYR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447645
Associated spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
[32P] ATP in vitro ( 95 ) , [32P] bio-synthetic labeling ( 146 ) , immunoassay ( 90 ) , immunoprecipitation ( 4 , 90 , 95 ) , mass spectrometry ( 1 , 2 , 4 , 7 , 12 , 14 , 15 , 16 , 17 , 18 , 19 , 38 , 39 , 40 , 41 , 42 , 43 , 45 , 46 , 47 , 48 , 49 , 51 , 52 , 53 , 54 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 66 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 91 , 93 , 94 , 97 , 98 , 99 , 101 , 102 , 103 , 104 , 108 , 115 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 , 126 , 127 , 130 , 131 , 132 , 133 , 134 , 135 ) , mutation of modification site ( 4 , 88 , 136 ) , peptide sequencing ( 35 ) , phospho-antibody ( 3 , 5 , 8 , 10 , 11 , 13 , 21 , 24 , 25 , 26 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 37 , 44 , 50 , 55 , 64 , 67 , 68 , 88 , 89 , 90 , 96 , 100 , 105 , 106 , 107 , 109 , 110 , 111 , 112 , 113 , 114 , 125 , 128 , 129 , 136 , 137 , 138 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 146 , 147 ) , phosphopeptide mapping ( 146 ) , western blotting ( 3 , 4 , 5 , 8 , 10 , 11 , 13 , 21 , 24 , 25 , 26 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 37 , 44 , 50 , 55 , 64 , 67 , 68 , 88 , 89 , 90 , 96 , 100 , 105 , 106 , 107 , 109 , 110 , 111 , 112 , 113 , 114 , 129 , 136 , 137 , 138 , 139 , 140 , 141 , 143 , 144 , 146 , 147 )
Disease tissue studied:
chondrosarcoma ( 3 ) , kidney cancer ( 107 ) , leukemia ( 52 , 53 , 54 , 93 , 94 , 132 ) , chronic myelogenous leukemia ( 93 , 94 , 132 ) , liver cancer ( 4 ) , lung cancer ( 76 , 77 , 78 , 79 , 82 , 83 , 84 , 85 , 86 , 87 , 100 ) , non-small cell lung cancer ( 76 , 77 , 78 , 82 , 83 , 84 , 85 , 86 , 87 ) , neuroblastoma ( 30 ) , testicular cancer ( 40 , 42 ) , type 2 diabetes ( 44 ) , Turner-like syndrome ( 62 , 63 )
Relevant cell line - cell type - tissue:
'brain, cerebellum' ( 35 ) , 'brain, embryonic' ( 81 , 101 ) , 'brain, hippocampus' ( 105 ) , 'brain, striatum' ( 144 ) , 'muscle, skeletal' ( 138 ) , 'neuron, cortical'-brain ( 10 ) , 'renal, podocyte' ( 37 ) , 'stem, embryonic' ( 45 , 46 , 47 , 48 ) , 10T1/2 (fibroblast) ( 73 ) , 293 (epithelial) ( 8 , 64 , 90 , 146 ) , 293T (epithelial) ( 5 ) , 32D (myeloid) [IRS1 (mouse)] ( 141 ) , 32Dcl3 (myeloid) ( 49 ) , 32Dcl3 (myeloid) [FLT3 (mouse), transfection, chimera with human FLT3-ITD mutant (corresponding to wild type P36888 ~aa 525-695 ETILLNS...IFEYCC)] ( 49 ) , 3T3 (fibroblast) ( 21 ) , 3T3 (fibroblast) [INSR (human)] ( 146 ) , 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] ( 143 ) , 3T3-L1 (fibroblast) ( 24 ) , 831/13 ( 133 , 134 , 135 ) , adipocyte ( 112 ) , adipose tissue ( 95 ) , aorta ( 106 ) , B lymphocyte-spleen ( 109 ) , BAEC (endothelial) ( 107 ) , BaF3 ('B lymphocyte, precursor') ( 51 , 93 , 94 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 , 126 , 127 , 131 , 132 ) , BaF3 ('B lymphocyte, precursor') [JAK3 (human), transfection] ( 1 ) , BMMC (mast) ( 34 ) , bone marrow ( 111 ) , brain ( 13 , 14 , 16 , 17 , 39 , 80 , 91 , 102 , 130 ) , C2C12 (myoblast) ( 69 , 70 , 71 ) , C2C12-D (muscle cell) ( 103 , 104 ) , chondrocyte ( 3 ) , COS (fibroblast) ( 142 ) , embryo ( 17 ) , ES (stem) ( 8 , 90 ) , F9 (testicular) ( 40 ) , FL5.12 (lymphoid) ( 137 ) , GD25 (fibroblast) ( 140 ) , heart ( 60 , 61 , 62 , 63 , 99 , 110 ) , Hepa 1-6 (epithelial) ( 66 ) , HepG2 (hepatic) ( 4 ) , JB (epithelial) ( 145 ) , liver ( 4 , 17 , 97 , 98 , 108 ) , lung ( 76 , 77 , 78 , 100 ) , lung [EGFR (mouse), transgenic] ( 79 ) , lung [GPX1 (mouse), homozygous knockout] ( 11 ) , macrophage-bone marrow ( 38 , 125 ) , macrophage-bone marrow [DUSP1 (mouse), homozygous knockout] ( 38 ) , macrophage-peritoneum ( 29 , 147 ) , mast-bone marrow ( 109 , 113 ) , mast-bone marrow [PTPRA (mouse), homozygous knockout] ( 67 ) , mast-bone marrow [SHP-2 (mouse), homozygous knockout] ( 50 ) , MEF (fibroblast) ( 12 , 56 , 59 , 72 , 88 , 95 , 96 , 110 , 114 , 136 , 145 ) , MEF (fibroblast) [DOK1 (mouse)] ( 89 ) , MEF (fibroblast) [HRas (mouse), HRas V12] ( 57 , 58 ) , MEF (fibroblast) [IGF1R (mouse)] ( 128 ) , MEF (fibroblast) [JNK1 (mouse), transfection] ( 64 ) , MEF (fibroblast) [LKB1 (mouse)] ( 139 ) , MEF (fibroblast) [PKR (mouse), homozygous knockout] ( 33 , 44 ) , MEF (fibroblast) [Raptor (mouse), knockdown] ( 12 ) , MEF (fibroblast) [RICTOR (mouse), knockdown] ( 12 ) , microvessel-kidney ( 107 ) , mLEC (epithelial) ( 28 ) , MMTV-PyMT (breast cell) [JNK2 (mouse), homozygous knockout] ( 31 ) , myocyte-heart ( 32 , 110 ) , Neuro-2a (neuron) ( 30 ) , neuron:postsynaptic density-'brain, hippocampus, CA1 region' ( 2 ) , P19 (testicular) ( 42 ) , PYS-2 (epithelial) ( 43 ) , RAW 264 (macrophage) ( 129 ) , RAW 264.7 (macrophage) ( 7 , 52 , 53 , 54 , 55 ) , RCS (chondrocyte) ( 3 ) , stromal ( 26 ) , SYF (fibroblast) [Src (mouse), transfection] ( 15 ) , T lymphocyte [FOXO1A (mouse), transgenic] ( 25 ) , T lymphocyte-lymph node ( 109 ) , vascular smooth muscle cell ('muscle, smooth') ( 68 )

Upstream Regulation
Regulatory protein:
Bcl-10 (mouse) ( 109 ) , CARD11 (mouse) ( 109 ) , Cot (mouse) ( 128 ) , CTNNB1 (mouse) ( 64 ) , DUSP1 (mouse) ( 35 ) , DUSP19 (mouse) ( 142 ) , DUSP3 (mouse) ( 142 ) , eNOS (mouse) ( 112 ) , FGF18 (mouse) ( 3 ) , FOXP1 (mouse) ( 25 ) , Fyn (mouse) ( 5 ) , GAB2 (mouse) ( 113 ) , GPX1 (human) ( 11 ) , HGK (mouse) ( 110 ) , IGF1R (mouse) ( 137 ) , JNK1 (human) ( 64 ) , MEK1 (mouse) ( 90 ) , MEKK1 (mouse) ( 8 ) , PKR (mouse) ( 33 , 44 ) , PPP1CC (human) ( 68 ) , PXN (mouse) ( 116 ) , RHOA (mouse) ( 107 ) , ROCK1 (human) ( 92 ) , SHP-2 (mouse) ( 50 ) , Src (mouse) ( 21 ) , Syk (mouse) ( 107 ) , TAK1 (mouse) ( 110 )
Putative in vivo kinases:
MKK4 (mouse) ( 90 )
Kinases, in vitro:
MKK4 (mouse) ( 6 , 90 )
Treatments:
acadesine ( 139 ) , activin ( 90 ) , adriamycin ( 33 ) , AG1478 ( 37 ) , AG490 ( 8 ) , alpha-lipoic_acid ( 30 ) , anisomycin ( 24 , 147 ) , anti-CD3/CD28 ( 25 ) , anti-FcRII ( 107 ) , anti-IgE ( 50 ) , Aplidin ( 136 ) , benzo(a)pyrene ( 100 ) , bradykinin ( 112 ) , ciclopirox_olamine ( 28 ) , cigarette_smoke ( 11 ) , cisplatin ( 88 ) , cold_water_stress ( 105 ) , CRP ( 107 ) , cyclic_stretch ( 37 ) , DMNQ ( 68 ) , dronabinol ( 10 ) , DTT ( 35 ) , EGF ( 8 , 116 ) , ether ( 105 ) , fasting ( 4 ) , food deprivation ( 105 ) , glucose ( 24 , 32 , 37 ) , H2O2 ( 37 ) , HA-1077 ( 92 ) , hydroxylamine ( 112 ) , hypoxia ( 32 ) , hypoxia/reoxygenation ( 32 ) , IGF-1 ( 137 ) , IgG ( 125 ) , IL-1b ( 128 ) , IL-33 ( 7 ) , IL-6 ( 106 ) , insulin ( 24 , 112 , 141 , 146 ) , ionizing_radiation ( 88 ) , ionomycin ( 109 ) , JNK_inhibitor_I ( 106 ) , licochalcone_A ( 55 ) , licochalcone_B ( 55 ) , licochalcone_C ( 55 ) , licochalcone_D ( 55 ) , low_glucose ( 37 ) , LPS ( 29 , 38 , 55 , 125 ) , LY294002 ( 141 ) , M-CSF ( 111 ) , metamfetamine ( 144 ) , mitomycin_C ( 88 ) , MK-591 ( 13 ) , muramyl_dipeptide ( 26 ) , NSC697923 ( 8 ) , NTCU ( 100 ) , okadaic_acid ( 147 ) , palmitate ( 21 , 95 ) , PD169316 ( 138 , 145 ) , PD98059 ( 106 , 138 , 141 , 145 ) , PGE2 ( 34 , 129 ) , phorbol_ester ( 109 , 116 , 147 ) , pomegranate_wine ( 100 ) , PP2 ( 137 ) , RANKL ( 111 , 129 ) , rapamycin ( 5 , 34 ) , SB202190 ( 145 ) , SCF ( 65 , 67 , 113 ) , serum ( 31 ) , serum_withdrawal ( 31 ) , siRNA ( 107 , 116 ) , sorbitol ( 142 ) , SP600125 ( 24 , 30 , 89 , 137 , 138 ) , TAK1_inhibitor ( 8 ) , TGF-alpha ( 90 ) , TGF-beta ( 8 , 90 ) , thapsigargin ( 5 , 44 ) , TNF ( 96 , 111 , 128 , 138 ) , Torin1 ( 34 ) , tunicamycin ( 35 ) , U0126 ( 89 ) , UV ( 88 , 114 , 143 , 145 ) , WIN ( 10 ) , wortmannin ( 34 ) , Y27632 ( 107 ) , zymosan ( 147 )

Downstream Regulation
Effects of modification on JNK1:
enzymatic activity, induced ( 90 ) , molecular association, regulation ( 64 ) , protein degradation ( 64 )
Effects of modification on biological processes:
apoptosis, induced ( 5 ) , cell motility, induced ( 90 ) , transcription, altered ( 64 ) , transcription, inhibited ( 90 )
Induce interaction with:
CTNNB1 (human) ( 64 ) , GSK3B (human) ( 64 )

References 

1

Degryse S, et al. (2017) Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia
28852199   Curated Info

2

Li J, et al. (2016) Long-term potentiation modulates synaptic phosphorylation networks and reshapes the structure of the postsynaptic interactome. Sci Signal 9, rs8
27507650   Curated Info

3

Cinque L, et al. (2015) FGF signalling regulates bone growth through autophagy. Nature 528, 272-5
26595272   Curated Info

4

Zhao Y, et al. (2015) RACK1 Promotes Autophagy by Enhancing the Atg14L-Beclin 1-Vps34-Vps15 Complex Formation upon Phosphorylation by AMPK. Cell Rep 13, 1407-17
26549445   Curated Info

5

Wang Y, Yamada E, Zong H, Pessin JE (2015) Fyn Activation of mTORC1 Stimulates the IRE1α-JNK Pathway, Leading to Cell Death. J Biol Chem 290, 24772-83
26306048   Curated Info

6

Yang J, et al. (2015) Pathological axonal death through a MAPK cascade that triggers a local energy deficit. Cell 160, 161-76
25594179   Curated Info

7

Pinto SM, et al. (2015) Quantitative phosphoproteomic analysis of IL-33-mediated signaling. Proteomics 15, 532-44
25367039   Curated Info

8

Charlaftis N, et al. (2014) The MEKK1 PHD ubiquitinates TAB1 to activate MAPKs in response to cytokines. EMBO J 33, 2581-96
25260751   Curated Info

9

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

10

Tortoriello G, et al. (2014) Miswiring the brain: Δ9-tetrahydrocannabinol disrupts cortical development by inducing an SCG10/stathmin-2 degradation pathway. EMBO J 33, 668-85
24469251   Curated Info

11

Geraghty P, et al. (2013) The Glutathione Peroxidase 1-Protein Tyrosine Phosphatase 1B-Protein Phosphatase 2A Axis. A Key Determinant of Airway Inflammation and Alveolar Destruction. Am J Respir Cell Mol Biol 49, 721-30
23590304   Curated Info

12

Robitaille AM, et al. (2013) Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science 339, 1320-3
23429704   Curated Info

13

Chu J, Lauretti E, Di Meco A, Praticò D (2013) FLAP pharmacological blockade modulates metabolism of endogenous tau in vivo . Transl Psychiatry 3, e333
24301651   Curated Info

14

Trinidad JC, et al. (2012) Global identification and characterization of both O-GlcNAcylation and phosphorylation at the murine synapse. Mol Cell Proteomics 11, 215-29
22645316   Curated Info

15

Ferrando IM, et al. (2012) Identification of targets of c-Src tyrosine kinase by chemical complementation and phosphoproteomics. Mol Cell Proteomics 11, 355-69
22499769   Curated Info

16

Goswami T, et al. (2012) Comparative phosphoproteomic analysis of neonatal and adult murine brain. Proteomics 12, 2185-9
22807455   Curated Info

17

Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201
22322096   Curated Info

18

Ren H (2011) CST Curation Set: 12906; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

19

Ren H (2011) CST Curation Set: 12897; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

20

Grebien F, et al. (2011) Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Cell 147, 306-19
22000011   Curated Info

21

Holzer RG, et al. (2011) Saturated fatty acids induce c-Src clustering within membrane subdomains, leading to JNK activation. Cell 147, 173-84
21962514   Curated Info

22

Hatziapostolou M, et al. (2011) Tumor progression locus 2 mediates signal-induced increases in cytoplasmic calcium and cell migration. Sci Signal 4, ra55
21868363   Curated Info

23

Ryu JM, Han HJ (2011) L-threonine regulates G1/S phase transition of mouse embryonic stem cells via PI3K/Akt, MAPKs, and mTORC pathways. J Biol Chem 286, 23667-78
21550972   Curated Info

24

Gao Z, et al. (2011) Sirtuin 1 (SIRT1) protein degradation in response to persistent c-Jun N-terminal kinase 1 (JNK1) activation contributes to hepatic steatosis in obesity. J Biol Chem 286, 22227-34
21540183   Curated Info

25

Feng X, et al. (2011) Transcription factor Foxp1 exerts essential cell-intrinsic regulation of the quiescence of naive T cells. Nat Immunol 12, 544-50
21532575   Curated Info

26

Kim YG, et al. (2011) The Nod2 sensor promotes intestinal pathogen eradication via the chemokine CCL2-dependent recruitment of inflammatory monocytes. Immunity 34, 769-80
21565531   Curated Info

27

Bard-Chapeau EA, et al. (2011) Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell 19, 629-39
21575863   Curated Info

28

Luo Y, et al. (2011) The fungicide ciclopirox inhibits lymphatic endothelial cell tube formation by suppressing VEGFR-3-mediated ERK signaling pathway. Oncogene 30, 2098-107
21217783   Curated Info

29

Liu X, et al. (2011) Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk. Nat Immunol 12, 416-24
21441935   Curated Info

30

Wang X, et al. (2011) Essential role of ERK activation in neurite outgrowth induced by α-lipoic acid. Biochim Biophys Acta 1813, 827-38
21295083   Curated Info

31

Mitra S, Lee JS, Cantrell M, Van den Berg CL (2011) c-Jun N-terminal kinase 2 (JNK2) enhances cell migration through epidermal growth factor substrate 8 (EPS8). J Biol Chem 286, 15287-97
21357683   Curated Info

32

Wei J, et al. (2011) c-Jun N-terminal kinase (JNK-1) confers protection against brief but not extended ischemia during acute myocardial infarction. J Biol Chem 286, 13995-4006
21324895   Curated Info

33

Peidis P, et al. (2011) Doxorubicin bypasses the cytoprotective effects of eIF2α phosphorylation and promotes PKR-mediated cell death. Cell Death Differ 18, 145-54
20559319   Curated Info

34

Kuehn HS, et al. (2011) Prostaglandin E2 activates and utilizes mTORC2 as a central signaling locus for the regulation of mast cell chemotaxis and mediator release. J Biol Chem 286, 391-402
20980255   Curated Info

35

Li B, et al. (2011) Differences in endoplasmic reticulum stress signalling kinetics determine cell survival outcome through activation of MKP-1. Cell Signal 23, 35-45
20727407   Curated Info

36

George J, et al. (2011) Resveratrol and black tea polyphenol combination synergistically suppress mouse skin tumors growth by inhibition of activated MAPKs and p53. PLoS One 6, e23395
21887248   Curated Info

37

Faour WH, Thibodeau JF, Kennedy CR (2010) Mechanical stretch and prostaglandin E2 modulate critical signaling pathways in mouse podocytes. Cell Signal 22, 1222-30
20362052   Curated Info

38

Weintz G, et al. (2010) The phosphoproteome of toll-like receptor-activated macrophages. Mol Syst Biol 6, 371
20531401   Curated Info

39

Wiśniewski JR, et al. (2010) Brain phosphoproteome obtained by a FASP-based method reveals plasma membrane protein topology. J Proteome Res 9, 3280-9
20415495   Curated Info

40

Zhou J (2010) CST Curation Set: 9105; Year: 2010; Biosample/Treatment: cell line, F9/untreated; Disease: testicular cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info

41

Zhou J (2010) CST Curation Set: 9104; Year: 2010; Biosample/Treatment: cell line, ES J1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info

42

Zhou J (2010) CST Curation Set: 9109; Year: 2010; Biosample/Treatment: cell line, P19/untreated; Disease: testicular cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info

43

Zhou J (2010) CST Curation Set: 9108; Year: 2010; Biosample/Treatment: cell line, PY2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info

44

Nakamura T, et al. (2010) Double-stranded RNA-dependent protein kinase links pathogen sensing with stress and metabolic homeostasis. Cell 140, 338-48
20144759   Curated Info

45

Tucker M (2009) CST Curation Set: 8089; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

46

Tucker M (2009) CST Curation Set: 8081; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

47

Tucker M (2009) CST Curation Set: 8088; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

48

Tucker M (2009) CST Curation Set: 8080; Year: 2009; Biosample/Treatment: cell line, embryonic stem cells (mouse)(PTEN)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

49

Choudhary C, et al. (2009) Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell 36, 326-39
19854140   Curated Info

50

McPherson VA, et al. (2009) SH2 domain-containing phosphatase-2 protein-tyrosine phosphatase promotes Fc(epsilon)RI-induced activation of Fyn and Erk pathways leading to TNF(alpha) release from bone marrow-derived mast cells. J Immunol 183, 4940-7
19786542   Curated Info

51

Moritz A (2009) CST Curation Set: 7223; Year: 2009; Biosample/Treatment: cell line, BaF3/serum starved; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

52

Possemato A (2009) CST Curation Set: 7168; Year: 2009; Biosample/Treatment: cell line, RAW 264.7/LPS; Disease: leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

53

Possemato A (2009) CST Curation Set: 7169; Year: 2009; Biosample/Treatment: cell line, RAW 264.7/MG132; Disease: leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

54

Possemato A (2009) CST Curation Set: 7167; Year: 2009; Biosample/Treatment: cell line, RAW 264.7/LPS; Disease: leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

55

Furusawa J, et al. (2009) Glycyrrhiza inflata-derived chalcones, Licochalcone A, Licochalcone B and Licochalcone D, inhibit phosphorylation of NF-kappaB p65 in LPS signaling pathway. Int Immunopharmacol 9, 499-507
19291859   Curated Info

56

Li Y (2009) CST Curation Set: 6297; Year: 2009; Biosample/Treatment: cell line, MEF/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

57

Li Y (2009) CST Curation Set: 6298; Year: 2009; Biosample/Treatment: cell line, MEF Ras v12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

58

Li Y (2009) CST Curation Set: 6299; Year: 2009; Biosample/Treatment: cell line, MEF Ras v12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

59

Li Y (2009) CST Curation Set: 6296; Year: 2009; Biosample/Treatment: cell line, MEF/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

60

Stokes M (2008) CST Curation Set: 5664; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

61

Stokes M (2008) CST Curation Set: 5665; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

62

Stokes M (2008) CST Curation Set: 5666; Year: 2008; Biosample/Treatment: cell line, Noonan Syndrome mouse heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

63

Stokes M (2008) CST Curation Set: 5667; Year: 2008; Biosample/Treatment: cell line, Noonan Syndrome mouse heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

64

Hu D, et al. (2008) c-Jun N-terminal kinase 1 interacts with and negatively regulates Wnt/beta-catenin signaling through GSK3beta pathway. Carcinogenesis 29, 2317-24
18952597   Curated Info

65

Simon C, et al. (2008) Lnk adaptor protein down-regulates specific Kit-induced signaling pathways in primary mast cells. Blood 112, 4039-47
18753636   Curated Info

66

Pan C, Gnad F, Olsen JV, Mann M (2008) Quantitative phosphoproteome analysis of a mouse liver cell line reveals specificity of phosphatase inhibitors. Proteomics 8, 4534-46
18846507   Curated Info

67

Samayawardhena LA, Pallen CJ (2008) Protein-tyrosine phosphatase alpha regulates stem cell factor-dependent c-Kit activation and migration of mast cells. J Biol Chem 283, 29175-85
18725415   Curated Info

68

Tchivilev I, et al. (2008) Identification of a protective role for protein phosphatase 1cgamma1 against oxidative stress-induced vascular smooth muscle cell apoptosis. J Biol Chem 283, 22193-205
18540044   Curated Info

69

Possemato A (2008) CST Curation Set: 4933; Year: 2008; Biosample/Treatment: cell line, C2C12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

70

Possemato A (2008) CST Curation Set: 4934; Year: 2008; Biosample/Treatment: cell line, C2C12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

71

Possemato A (2008) CST Curation Set: 4936; Year: 2008; Biosample/Treatment: cell line, C2C12/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

72

Luo W, et al. (2008) Global impact of oncogenic Src on a phosphotyrosine proteome. J Proteome Res 7, 3447-60
18563927   Curated Info

73

Li Y (2008) CST Curation Set: 4543; Year: 2008; Biosample/Treatment: cell line, 10T1/2/FGF; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

74

Rikova K (2008) CST Curation Set: 4481; Year: 2008; Biosample/Treatment: cell line, MD Ander a0859/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

75

Rikova K (2008) CST Curation Set: 4477; Year: 2008; Biosample/Treatment: cell line, MD Ander 1154/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

76

Rikova K (2008) CST Curation Set: 4438; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

77

Rikova K (2008) CST Curation Set: 4439; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

78

Rikova K (2008) CST Curation Set: 4440; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

79

Ren H (2008) CST Curation Set: 4335; Year: 2008; Biosample/Treatment: cell line, EGFR_WT/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

80

Zhou J (2008) CST Curation Set: 4322; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

81

Zhou J (2008) CST Curation Set: 4323; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

82

Rikova K (2008) CST Curation Set: 4249; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

83

Rikova K (2008) CST Curation Set: 4250; Year: 2008; Biosample/Treatment: tissue, lung/Tarceva; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

84

Rikova K (2008) CST Curation Set: 4251; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

85

Rikova K (2008) CST Curation Set: 4252; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

86

Rikova K (2008) CST Curation Set: 4253; Year: 2008; Biosample/Treatment: tissue, lung/Tarceva; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

87

Rikova K (2008) CST Curation Set: 4254; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

88

Yogev O, et al. (2008) DNA damage-dependent translocation of B23 and p19 ARF is regulated by the Jun N-terminal kinase pathway. Cancer Res 68, 1398-406
18316603   Curated Info

89

Hosooka T, et al. (2008) Dok1 mediates high-fat diet-induced adipocyte hypertrophy and obesity through modulation of PPAR-gamma phosphorylation. Nat Med 14, 188-93
18204460   Curated Info

90

Takatori A, et al. (2008) Differential transmission of MEKK1 morphogenetic signals by JNK1 and JNK2. Development 135, 23-32
18032450   Curated Info

91

Ballif BA, Carey GR, Sunyaev SR, Gygi SP (2008) Large-scale identification and evolution indexing of tyrosine phosphorylation sites from murine brain. J Proteome Res 7, 311-8
18034455   Curated Info

92

Ongusaha PP, et al. (2008) Identification of ROCK1 as an upstream activator of the JIP-3 to JNK signaling axis in response to UVB damage. Sci Signal 1, ra14
19036714   Curated Info

93

Gu T (2007) CST Curation Set: 3406; Year: 2007; Biosample/Treatment: cell line, Baf3(PLXSN-NEO-FLT3/ITD)/IL3 withdrawal; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

94

Gu T (2007) CST Curation Set: 3407; Year: 2007; Biosample/Treatment: cell line, Baf3(PLXSN-NEO-FLT3/ITD)/IL3 withdrawal; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

95

Jaeschke A, Davis RJ (2007) Metabolic stress signaling mediated by mixed-lineage kinases. Mol Cell 27, 498-508
17679097   Curated Info

96

Schlaepfer DD, et al. (2007) Tumor necrosis factor-alpha stimulates focal adhesion kinase activity required for mitogen-activated kinase-associated interleukin 6 expression. J Biol Chem 282, 17450-9
17438336   Curated Info

97

Guo A (2007) CST Curation Set: 2985; Year: 2007; Biosample/Treatment: tissue, liver/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

98

Guo A (2007) CST Curation Set: 2986; Year: 2007; Biosample/Treatment: tissue, liver/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

99

Guo A (2007) CST Curation Set: 2827; Year: 2007; Biosample/Treatment: tissue, heart/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

100

Khan N, et al. (2007) Oral consumption of pomegranate fruit extract inhibits growth and progression of primary lung tumors in mice. Cancer Res 67, 3475-82
17389758   Curated Info

101

Guo A (2007) CST Curation Set: 2672; Year: 2007; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

102

Guo A (2007) CST Curation Set: 2675; Year: 2007; Biosample/Treatment: tissue, brain/LY; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

103

Guo A (2007) CST Curation Set: 2564; Year: 2007; Biosample/Treatment: cell line, C2C12-D/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

104

Guo A (2007) CST Curation Set: 2565; Year: 2007; Biosample/Treatment: cell line, C2C12-D/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

105

Ikeda Y, Ishiguro K, Fujita SC (2007) Ether stress-induced Alzheimer-like tau phosphorylation in the normal mouse brain. FEBS Lett 581, 891-7
17289030   Curated Info

106

Andreozzi F, et al. (2007) Interleukin-6 impairs the insulin signaling pathway, promoting production of nitric oxide in human umbilical vein endothelial cells. Mol Cell Biol 27, 2372-83
17242212   Curated Info

107

Xu JW, et al. (2007) C-reactive protein suppresses insulin signaling in endothelial cells: role of spleen tyrosine kinase. Mol Endocrinol 21, 564-73
17095576   Curated Info

108

Villén J, Beausoleil SA, Gerber SA, Gygi SP (2007) Large-scale phosphorylation analysis of mouse liver. Proc Natl Acad Sci U S A 104, 1488-93
17242355   Curated Info

109

Blonska M, et al. (2007) The CARMA1-Bcl10 signaling complex selectively regulates JNK2 kinase in the T cell receptor-signaling pathway. Immunity 26, 55-66
17189706   Curated Info

110

Xie M, et al. (2006) A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc Natl Acad Sci U S A 103, 17378-83
17085580   Curated Info

111

Huang H, et al. (2006) Osteoclast differentiation requires TAK1 and MKK6 for NFATc1 induction and NF-kappaB transactivation by RANKL. Cell Death Differ 13, 1879-91
16498455   Curated Info

112

Beard KM, Lu H, Ho K, Fantus IG (2006) Bradykinin augments insulin-stimulated glucose transport in rat adipocytes via endothelial nitric oxide synthase-mediated inhibition of Jun NH2-terminal kinase. Diabetes 55, 2678-87
17003331   Curated Info

113

Yu M, et al. (2006) The scaffolding adapter Gab2, via Shp-2, regulates kit-evoked mast cell proliferation by activating the Rac/JNK pathway. J Biol Chem 281, 28615-26
16873377   Curated Info

114

Jaeschke A, et al. (2006) JNK2 is a positive regulator of the cJun transcription factor. Mol Cell 23, 899-911
16973441   Curated Info

115

Gu T (2006) CST Curation Set: 1516; Year: 2006; Biosample/Treatment: cell line, Thom/serum starved; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

116

Tatsumi Y, et al. (2006) Involvement of the paxillin pathway in JB6 Cl41 cell transformation. Cancer Res 66, 5968-74
16740738   Curated Info

117

Goss V (2006) CST Curation Set: 1200; Year: 2006; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

118

Goss V (2005) CST Curation Set: 860; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

119

Goss V (2005) CST Curation Set: 861; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

120

Goss V (2005) CST Curation Set: 847; Year: 2005; Biosample/Treatment: cell line, BaF3/serum starved; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

121

Goss V (2005) CST Curation Set: 848; Year: 2005; Biosample/Treatment: cell line, BaF3/serum starved; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

122

Gu T (2005) CST Curation Set: 844; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

123

Gu T (2005) CST Curation Set: 845; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

124

Gu T (2005) CST Curation Set: 846; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

125

Lucas M, Zhang X, Prasanna V, Mosser DM (2005) ERK activation following macrophage FcgammaR ligation leads to chromatin modifications at the IL-10 locus. J Immunol 175, 469-77
15972681   Curated Info

126

Goss V (2005) CST Curation Set: 813; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

127

Goss V (2005) CST Curation Set: 815; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

128

Das S, et al. (2005) Tpl2/cot signals activate ERK, JNK, and NF-kappaB in a cell-type and stimulus-specific manner. J Biol Chem 280, 23748-57
15833743   Curated Info

129

Kobayashi Y, et al. (2005) Prostaglandin E2 enhances osteoclastic differentiation of precursor cells through protein kinase A-dependent phosphorylation of TAK1. J Biol Chem 280, 11395-403
15647289   Curated Info

130

Ballif BA, et al. (2004) Phosphoproteomic analysis of the developing mouse brain. Mol Cell Proteomics 3, 1093-101
15345747   Curated Info

131

Goss V (2004) CST Curation Set: 476; Year: 2004; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

132

Goss V (2004) CST Curation Set: 395; Year: 2004; Biosample/Treatment: cell line, BaF3/serum starved &'||' Tpo; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

133

Li Y (2004) CST Curation Set: 380; Year: 2004; Biosample/Treatment: cell line, 831/13/Serum starved; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

134

Li Y (2004) CST Curation Set: 381; Year: 2004; Biosample/Treatment: cell line, 831/13/Serum starved &'||' IGF; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

135

Li Y (2004) CST Curation Set: 382; Year: 2004; Biosample/Treatment: cell line, 831/13/Serum starved &'||' Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

136

Cuadrado A, et al. (2004) JNK activation is critical for Aplidin-induced apoptosis. Oncogene 23, 4673-80
15122339   Curated Info

137

Leahy M, Lyons A, Krause D, O'Connor R (2004) Impaired Shc, Ras, and MAPK activation but normal Akt activation in FL5.12 cells expressing an insulin-like growth factor I receptor mutated at tyrosines 1250 and 1251. J Biol Chem 279, 18306-13
14963047   Curated Info

138

de Alvaro C, Teruel T, Hernandez R, Lorenzo M (2004) Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner. J Biol Chem 279, 17070-8
14764603   Curated Info

139

Shaw RJ, et al. (2004) The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A 101, 3329-35
14985505   Curated Info

140

Pankov R, et al. (2003) Specific beta1 integrin site selectively regulates Akt/protein kinase B signaling via local activation of protein phosphatase 2A. J Biol Chem 278, 18671-81
12637511   Curated Info

141

Lee YH, Giraud J, Davis RJ, White MF (2003) c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade. J Biol Chem 278, 2896-902
12417588   Curated Info

142

Nakamura K, et al. (2002) A novel low-molecular-mass dual-specificity phosphatase, LDP-2, with a naturally occurring substitution that affects substrate specificity. J Biochem (Tokyo) 132, 463-70
12204117   Curated Info

143

Deng J, et al. (2002) Activation of GCN2 in UV-irradiated cells inhibits translation. Curr Biol 12, 1279-86
12176355   Curated Info

144

Jayanthi S, McCoy MT, Ladenheim B, Cadet JL (2002) Methamphetamine causes coordinate regulation of Src, Cas, Crk, and the Jun N-terminal kinase-Jun pathway. Mol Pharmacol 61, 1124-31
11961130   Curated Info

145

Zhang Y, et al. (2001) UVA induces Ser381 phosphorylation of p90RSK/MAPKAP-K1 via ERK and JNK pathways. J Biol Chem 276, 14572-80
11278279   Curated Info

146

de Ruiter ND, et al. (2000) Ras-dependent regulation of c-Jun phosphorylation is mediated by the Ral guanine nucleotide exchange factor-Ral pathway. Mol Cell Biol 20, 8480-8
11046144   Curated Info

147

Gijón MA, et al. (2000) Cytosolic phospholipase A2 is required for macrophage arachidonic acid release by agonists that Do and Do not mobilize calcium. Novel role of mitogen-activated protein kinase pathways in cytosolic phospholipase A2 regulation. J Biol Chem 275, 20146-56
10867029   Curated Info